Trial · NCT02558231
Adverse events488
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 488
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 14 | 119 | |
| other | Anaemia | Blood and lymphatic system disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 11 | 127 | |
| other | Iron Deficiency Anaemia | Blood and lymphatic system disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 6 | 119 | |
| other | Iron Deficiency Anaemia | Blood and lymphatic system disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 5 | 127 | |
| other | Palpitations | Cardiac disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 14 | 119 | |
| other | Palpitations | Cardiac disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 11 | 127 | |
| other | Abdominal Distension | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 6 | 119 | |
| other | Abdominal Distension | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 4 | 127 | |
| other | Abdominal Pain | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 7 | 119 | |
| other | Abdominal Pain | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 6 | 127 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 8 | 119 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 7 | 127 | |
| other | Constipation | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 7 | 119 | |
| other | Constipation | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 9 | 127 | |
| other | Diarrhoea | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 66 | 119 | |
| other | Diarrhoea | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 41 | 127 | |
| other | Dyspepsia | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 27 | 119 | |
| other | Dyspepsia | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 17 | 127 | |
| other | Gastrooesophageal Reflux Disease | Gastrointestinal disorders | Triple Oral Therapy (Macitentan, Tadalafil, and Selexipag) | 11 | 119 | |
| other | Gastrooesophageal Reflux Disease | Gastrointestinal disorders | Double Oral Therapy (Macitentan, Tadalafil, and Placebo) | 18 | 127 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02558231/events